Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $32.42 USD
Change Today +0.36 / 1.12%
Volume 230.6K
As of 8:10 PM 06/2/15 All times are local (Market data is delayed by at least 15 minutes).

acceleron pharma inc (XLRN) Snapshot

Open
$32.00
Previous Close
$32.06
Day High
$32.80
Day Low
$31.12
52 Week High
12/8/14 - $48.50
52 Week Low
09/9/14 - $23.61
Market Cap
1.1B
Average Volume 10 Days
158.2K
EPS TTM
$-1.67
Shares Outstanding
32.8M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ACCELERON PHARMA INC (XLRN)

Related News

No related news articles were found.

acceleron pharma inc (XLRN) Related Businessweek News

No Related Businessweek News Found

acceleron pharma inc (XLRN) Details

Acceleron Pharma Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of protein therapeutics for cancer and rare diseases. The company is developing luspatercept and sotatercept therapeutic candidates, which are in Phase 3 clinical trials used to treat anemia and associated complications in patients with ß-thalassemia and myelodysplastic syndromes. The sotatercept therapeutic candidate is also used to increase bone mineral density; and to treat the final stage of chronic kidney disease and end-stage renal disease. It is also developing dalantercept therapeutic candidate to treat renal cell carcinoma and hepatocellular carcinoma; and ACE-083 that is in Phase 1 clinical trial used to promote muscle growth and function in specific treated muscle groups. It has collaboration, license, and option agreement with Celgene Corporation. The company was formerly known as Phoenix Pharma, Inc. Acceleron Pharma Inc. was founded in 2003 and is headquartered in Cambridge, Massachusetts.

83 Employees
Last Reported Date: 03/2/15
Founded in 2003

acceleron pharma inc (XLRN) Top Compensated Officers

Founder, Chief Executive Officer, President a...
Total Annual Compensation: $460.0K
Chief Financial Officer, Senior Vice Presiden...
Total Annual Compensation: $325.0K
Chief Operating Officer and Executive Vice Pr...
Total Annual Compensation: $335.0K
Chief Medical Officer and Executive Vice Pres...
Total Annual Compensation: $392.0K
Senior Vice President, General Counsel and Se...
Total Annual Compensation: $335.0K
Compensation as of Fiscal Year 2014.

acceleron pharma inc (XLRN) Key Developments

Acceleron Pharma, Inc. Presents at Jefferies 2015 Global Healthcare Conference, Jun-01-2015 04:00 PM

Acceleron Pharma, Inc. Presents at Jefferies 2015 Global Healthcare Conference, Jun-01-2015 04:00 PM. Venue: The Grand Hyatt Hotel, New York, New York, United States. Speakers: John L. Knopf, Founder, Chief Executive Officer, President and Director.

Acceleron Pharma, Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015

Acceleron Pharma, Inc. reported unaudited consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported collaboration revenue of $4,420,000 compared to $3,307,000 a year ago. Loss from operations was $15,059,000 compared to $12,208,000 a year ago. Net loss applicable to common stockholders was $14,574,000 or $0.45 per basic and diluted share compared to $9,120,000 or $0.30 per basic and diluted share a year ago.

Acceleron Pharma Inc. Announces Preliminary Data from the Ongoing Phase 2 Clinical Trial of Luspatercept in Patients with Lower Risk Myelodysplastic Syndromes

Acceleron Pharma Inc. announced preliminary data from the ongoing phase 2 clinical trial of luspatercept in patients with lower risk myelodysplastic syndromes (MDS). The data showed that luspatercept increased hemoglobin levels and enabled many patients to become transfusion independent. Key preliminary data from the presentation are highlighted below: The ongoing phase 2 clinical trial is fully enrolled and data from 44 of the 58 patients was available for efficacy analyses. 17 of these 44 patients were enrolled in the expansion cohort, using the planned phase 3 dosing regimen, whose data had not been previously presented. Luspatercept was generally well-tolerated with the majority of adverse events (AE) being mild to moderate (grade 1 or 2). There were two possibly related serious adverse events of muscle pain and worsening of general condition. In the higher dose groups (0.75 to 1.75 mg/kg administered subcutaneously every three weeks): 54% achieved the International Working Group (IWG) hematologic improvement-erythroid (HI-E) threshold of efficacy. 36% of patients who received red blood cell transfusions during the 8 weeks prior to treatment in the study achieved transfusion independence for at least 8 weeks during the study. Ring sideroblasts (RS) are a type of abnormal red blood cell (RBC) precursor cell in the bone marrow. These ring sideroblasts are associated with ineffective erythropoiesis and anemia. When at least 15% of the cells in an MDS patient’s bone marrow are ring sideroblasts, this patient is considered RS positive. At least 30% of all MDS patients are RS positive, and the proportion is likely even greater within the lower risk segment of all MDS patients. In the RS positive patients in the higher dose groups treated with luspatercept, 63% achieved IWG HI-E and 39% achieved transfusion independence.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
XLRN:US $32.42 USD +0.36

XLRN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for XLRN.
View Industry Companies
 

Industry Analysis

XLRN

Industry Average

Valuation XLRN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 66.4x
Price/Book 7.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales 60.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ACCELERON PHARMA INC, please visit www.acceleronpharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.